pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
ROCHE · news · pharmadog
← back to ROCHE
News mentioning ROCHE
412
stories
Oct 6, 26
Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial
biopharma dive
Oct 6, 26
AbbVie, Genmab's Epkinly sets ‘new standard of care’ in first-line lymphoma in Phase 3
biospace
Oct 6, 26
AbbVie, Genmab trot out first-line DLBCL win for Epkinly in challenge to Polivy
endpoints
Oct 6, 26
BioSpace 40 Under 40 winners make their mark on biopharma
biospace
Oct 5, 26
Genentech AI leader Richard Bonneau leaves pharma in latest exit
endpoints
Oct 5, 26
Genentech pens $1.27B deal to access Alector’s preclinical blood-brain barrier asset
biospace
Oct 5, 26
Roche enlists Alector in Parkinson's deal, paying $100M upfront
endpoints
Oct 5, 26
Optogenetics researchers win a Nobel Prize; Roche bets on Alector brain drug
biopharma dive
Oct 5, 26
Genentech pays Alector $100M for preclinical Parkinson’s prospect
fiercebiotech
Oct 5, 26
Roivant, the 'inveterate drug hunters', enters commercial era with Lisraya
biospace
Oct 2, 26
This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking
biopharma dive
Oct 2, 26
Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen
biospace
Oct 2, 26
‘We’ve been taking our time’: Buzzy AI biotech Xaira reveals antibody platform, first taste of pipeline
fiercebiotech
Oct 1, 26
3 takeaways from a European obesity scientific meeting
biopharma dive
Oct 1, 26
Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease
biospace
Oct 1, 26
Roche launches simultaneous screening test for SMA, SCID and SCD
fiercebiotech
Sep 30, 26
FDA starts review of Roche’s multiple sclerosis pill
biopharma dive
Sep 30, 26
STAT+: Pharmalittle: We’re reading about Beam suing over IP theft, a Trump rule on importing meds, and more
stat
Sep 30, 26
Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
fiercebiotech
Sep 30, 26
Roche, Zealand see phase 2 amylin weight loss peak at mid-dose, start pivotal program
fiercebiotech
Sep 29, 26
#EASD26: Zealand and Roche's amylin works best at middle dose, trails Lilly's
endpoints
Sep 29, 26
STAT+: Lawmakers urge Trump to rethink new rule that could restrict imported meds from Canada and overseas
stat
Sep 29, 26
Canadian $5M accelerated clinical trial program cuts start-up to 45 days
fiercebiotech
Sep 29, 26
Roche cuts muscle-sparing obesity drug after mid-stage disappointment
biospace
Sep 29, 26
STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
stat
Sep 29, 26
Summit snags $2B investment from AstraZeneca, clearing financial overhang
biospace
Sep 29, 26
STAT+: Pharmalittle: We’re reading about Novo licensing a Chinese obesity pill, Merck pulling an antibiotic, and more
stat
Sep 29, 26
AI health startup Ortet launches with $500M and co-founders from Genentech
endpoints
Sep 28, 26
STAT+: Merck discontinues a crucial antibiotic despite concerns over superbug resistance
stat
Sep 28, 26
‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the future
fiercebiotech
← prev
page 6 of 14
next →